Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(9):567; doi:10.1093/jnci/djj195
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Sentinel Lymph Node Biopsy Versus Axillary Treatment

Sentinel lymph node biopsy in women with operable breast cancer is used routinely in some countries for staging of the axilla despite limited data on morbidity and mortality outcomes. Mansel et al. (p. 599) conducted a multicenter randomized trial in patients with clinically node-negative invasive breast cancer to compare arm and shoulder morbidity and quality of life between those who received sentinel lymph node biopsy and those who received standard axillary treatment. In intention-to-treat analyses, the sentinel lymph node biopsy group experienced less lymphedema and sensory loss at 12 months than . . . [Full Text of this Article]

Therapy Completion by Colon Cancer Patients

Reporting of Clinical Trials in Hodgkin Lymphoma

Adenovirus-Mediated Glioma Cell Death

Validation of a Lung Cancer Prediction Model

PK/PD Technologies in Clinical Trials


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?